Breaking news

23andMe Files For Chapter 11: Anne Wojcicki Resigns Amid Struggles to Revive Company

In a bold and unexpected move, 23andMe has filed for Chapter 11 bankruptcy, signaling the company’s struggle to stay afloat amid mounting financial pressure. In its filing with the Eastern District of Missouri federal bankruptcy court, the DNA testing giant revealed it has initiated the process of selling its assets in an attempt to salvage what’s left of its business. Despite the looming uncertainty, 23andMe reassured customers that it would continue operations throughout the asset sale process, emphasizing that there would be no disruptions to how customer data is stored, managed, or protected.

If the bankruptcy court approves its Chapter 11 plan, 23andMe will embark on a 45-day window to solicit bids. If multiple buyers emerge, the company will hold an auction to maximize its value. A key condition for any potential buyer: they must adhere to legal requirements for handling customer data, a significant concern after recent breaches.

In a related shakeup, co-founder Anne Wojcicki, who once helmed the company, has stepped down as CEO. However, Wojcicki isn’t entirely distancing herself from the company—she will remain on 23andMe’s board and is reportedly preparing to bid on the company’s assets herself. Her resignation follows a failed attempt to take 23andMe private. Last month, she made a bid to acquire the company for $2.53 per share, but the deal collapsed when her partner, New Mountain Capital, pulled out. This was followed by a new bid this month, offering just 41 cents per share—a move swiftly rejected by the company’s board. In a statement on X (formerly Twitter), Wojcicki expressed her disappointment, but also her intent to pursue the company’s assets independently, citing her resignation as a strategic move to position herself better for the bidding process.

The Rise And Fall Of 23andMe

Once a market darling, 23andMe went public in 2021 through a merger with a Special Purpose Acquisition Company (SPAC), reaching a market cap of $6 billion. Wojcicki, a co-founder of the company, saw her fortune soar into the billions. But since then, the company’s stock has plummeted by over 99%, as it failed to reach profitability despite its promising start.

Adding fuel to the fire, the company suffered a major data breach in 2023, when hackers exploited recycled passwords to access sensitive user data. The breach involved over a million genetic data points, including information from high-profile individuals, and was shared across hacker forums. The exposed data included genetic ancestry, birth years, and even personal details of well-known tech figures such as Mark Zuckerberg and Elon Musk. In the aftermath, 23andMe settled in court, agreeing to pay $30 million and offer three years of security monitoring to those affected by the breach.

As 23andMe enters its next phase under bankruptcy proceedings, the company faces a steep uphill battle to regain trust and value. The fate of its assets—and its brand—now rests in the hands of potential buyers.

EU Records €220.5 Billion Pharmaceutical Trade Surplus In 2025

The European Union secured a historic trade surplus in medicinal and pharmaceutical products in 2025, according to a report from Eurostat. Export figures reached €366.2 billion while imports totaled €145.7 billion, leading to a surplus of €220.5 billion.

Robust Growth In Exports And Imports

Exports increased by 16.0% from €315.7 billion in 2024. Imports rose by 21.0% from €120.4 billion over the same period. The data show continued expansion in trade volumes across the sector.

Leading National Performances

Ireland recorded the highest exports to non-EU countries at €93.8 billion. Germany and Belgium followed with €67.9 billion and €38.5 billion, respectively. Italy led imports at €27.5 billion, with Belgium and Germany also recording significant volumes.

Global Trade Partnerships

The United States was the largest destination for EU exports, accounting for 43.8% or €160.6 billion. Switzerland followed with 16.3% (€59.7 billion), while the United Kingdom accounted for 5.6% (€20.6 billion). On the import side, the United States supplied 41.2% of total imports (€60.1 billion), followed by Switzerland at 28.4% (€41.4 billion) and China at 9.0% (€13.1 billion).

The Future Forbes Realty Global Properties
eCredo
Uol
Aretilaw firm

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter